DEFA14A: Better Choice Company Amends Arrangement Agreement, Eyes Acquisition of Choice Specialty Pharmacy Group
Proxy Statement Supplement
Better Choice Company Inc. supplements its proxy statement with details on a potential acquisition of Choice Specialty Pharmacy Group and an SRx debt conversion, while also extending the outside date for its arrangement agreement.
Summary
- Better Choice Company Inc. has issued a supplement to its proxy statement regarding the proposed arrangement with SRx Health Solutions.
- The supplement details a binding letter of intent to acquire an option to purchase Choice Specialty Pharmacy Group for $28.0 million, with $10.5 million paid in stock upon purchase of the option and the remaining $17.5 million in cash or stock.
- The option term runs from April 15, 2025, to October 15, 2025.
- SRx agreed to a debt conversion with a supplier, converting CAD$4.0 million of accounts payable into 875,000 common shares of SRx, valued at approximately CAD$4.2 million.
- The arrangement agreement's outside date has been extended from February 28, 2025, to April 15, 2025.
- The Combined Company's Board of Directors following the consummation of the transaction will consist of five members including Adesh A. Vora, Pharm. D., as Chairman, Michael Young, Lionel Conacher, Simon Conway, and David White.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document primarily provides updates on ongoing transactions, with both potential positives (acquisition, debt conversion) and risks (delisting) mentioned.
Positives
- The potential acquisition of Choice Specialty Pharmacy Group could expand the Combined Company's reach into specialty pharmacy.
- The debt conversion by SRx could improve its balance sheet.
- The extension of the outside date provides more time to finalize the arrangement.
Negatives
- If the Combined Company does not exercise the option to acquire Choice, nine-tenths of the shares issued for the option will be returned to the Combined Company and the remaining one-tenth of the shares for the Option will remain with Choice.
- Failure to meet NYSE Initial Listing Standards could result in delisting and adverse consequences for stockholders.
Risks
- The Combined Company may not meet NYSE Initial Listing Standards, potentially leading to delisting.
- Delisting from NYSE could result in reduced liquidity, decreased analyst coverage, and difficulty obtaining additional financing.
- The company's ability to obtain additional capital in the future is a risk factor.
- General economic factors and competition in the industry could impact results.
Future Outlook
The company is working to meet NYSE Initial Listing Standards and complete the arrangement with SRx. The potential acquisition of Choice Specialty Pharmacy Group is also a key focus.
Industry Context
The potential acquisition of Choice Specialty Pharmacy Group reflects a trend of consolidation in the specialty pharmacy sector, as companies seek to expand their services and reach in the market for high-cost, high-touch medications.
Comparison to Industry Standards
- The valuation of Choice Specialty Pharmacy Group at approximately 6x its 2024 adjusted EBITDA is within the typical range for acquisitions in the specialty pharmacy space.
- Comparable companies such as Diplomat Pharmacy (acquired by OptumRx) and BioScrip (acquired by Option Care Health) have been valued at similar multiples in past transactions.
- However, the ultimate success of the acquisition will depend on the Combined Company's ability to integrate Choice's operations and realize synergies.
Stakeholder Impact
- Shareholders face the risk of delisting if the Combined Company does not meet NYSE Initial Listing Standards.
- The potential acquisition of Choice Specialty Pharmacy Group could benefit shareholders if it leads to increased profitability.
- Employees of SRx and Choice Specialty Pharmacy Group may be affected by the arrangement and potential acquisition.
Next Steps
- The company needs to obtain approval from NYSE for initial listing of the Combined Company.
- The company needs to complete the arrangement with SRx.
- The company needs to decide whether to exercise the option to acquire Choice Specialty Pharmacy Group.
Key Dates
| Date | Description |
|---|---|
| January 28, 2025 | Date of the original proxy statement. |
| February 19, 2025 | Date of the special meeting of common stockholders, which was adjourned. |
| February 25, 2025 | Date of Amendment No. 3 to the Arrangement Agreement and Amendment No. 2 to the Plan of Arrangement. |
| February 28, 2025 | Original Outside Date of the Arrangement Agreement. |
| March 3, 2025 | Approximate date of SRx's debt conversion agreement with its supplier. |
| March 7, 2025 | Date of the supplement to the proxy statement and the binding letter of intent with Choice Specialty Pharmacy Group. |
| March 21, 2025 | Rescheduled date of the special meeting of common stockholders. |
| April 15, 2025 | New Outside Date of the Arrangement Agreement and start date of the Option term. |
| October 15, 2025 | Expiration date of the Option term. |
Keywords
Arrangement, Acquisition, SRx, Better Choice Company, Choice Specialty Pharmacy Group, Debt Conversion, NYSE, Listing Standards, Proxy Statement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.